

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)
D-2947CIP

Application Number

Pending

Applicant(s)
Stephen Donovan

Filing Date

Herewith

Group Art Unit

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>CMK</i>	01	5,378,688	01-03-1995	Nett, et al.			02-14-1992
	02	5,459,127	10-17-1995	Felgner et al.			09-16-1993
	03	5,631,229	05-20-1997	Nett et al.			07-07-1993
	04	5,989,545	11-23-1999	Foster et al.			04-16-1996
	05	6,005,086	12-21-1999	Evans et al.			01-13-1995
	06	09/692,811		Donovan			10-20-2000
	07	09/288,326		Aoki & Sachs			04-08-1999
<i>CMK</i>	08	09/620,840		Steward et al.			07-21-2000

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>CMK</i>	09	"Immunohistochemical Study of Syntain-1 and Snap-25 in The Pituitaries of Mouse, Guinea Pig and Cat", E. Salinas et al. APPTLA 49, pp. 61-64, 1999
<i>CMK</i>	10	"Hormonal Regulation of Endometriosis and the Rationales and Effects of Gonadotrophin-Releasing Hormone Agonist Treatment: A Review", I.A. Bergqvist, HUMAN REPRODUCTION, vol. 10, no. 2, pp. 446-452, 1995

EXAMINER

John

DATE CONSIDERED

4/17/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) D-2947CIP	Application Number Pending
Applicant(s) Stephen Donovan	
Filing Date Herewith	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
CK	11	"Management of pituitary gonadal function via gonadotrophin releasing hormone (GnRH) antagonists, including ovulation induction by co-administration of either gonadotrophins or pulsatile GnRH" Keith Gordon et al. HUMAN REPRODUCTION vol. 8, Suppl2, pp 204-209, 1993
	12	"Targeting drugs to the brain by redox chemical delivery systems", Laszlo Prokai et al., John Wiley & Sons, Inc. Med Res Rev, 20, No. 5, pp. 367-416, 2000
	13	"New Advances in the Transport of Doxorubicin through the Blood-Brain Barrier by a Peptide Vector-Mediated Strategy", Christophe Rousselle et al., MOLECULAR PHARMACOLOGY, 57:679-686, 2000
	14	"Gonadotropin-Releasing Hormone Receptor: Gene Structure, Expression and Regulation", Peter C.K. Leung and Chun Peng. BIOLOGICAL SIGNALS, 1996;5:63-69
	15	"Nucleotide Sequence Analyses Predict that Human Pituitary and Human Placental Gonadotropin-Releasing Hormone Receptors have Identical Primary Structures", Timothy A. Boyle et al., ENDOCRINE, vol. 9, no. 3, 281-287, December 1998
	16	"Transporter-Mediated Permeation of Drugs Across the Blood-Brain Barrier", Ikumi Tamai and Akira Tsuji, JOURNAL OF PHARMACEUTICAL SCIENCES, vol 89, no. 11, November 2000
	17	"Accumulation of Synaptosomal-Associated Protein of 25kDa (SNAP-25) and Other Proteins Associated with the Secretory Pathway in GH4C1 Cells Upon Treatment with Estradiol, Insulin, and Epidermal Growth Factor", Min S. Lee et al., ENDOCRINOLOGY, vol. 141, no. 9, pp. 3485-3492, 2000
	18	"Localization and Physiological Regulation of the Exocytosis Protein SNAP-25 in the Brain and Pituitary Gland of Xenopus laevis", S.M. Kolk et al. JOURNAL OF NEUROENDOCRINOLOGY, 2000, vol. 12, 694-706
	19	"MCB 3320 Peptide Hormones" William S. Messer, Jr., http://www.neurosci.pharm.utoledo.edu/MCB3320/TRH.htm , March 15, 2000
	20	"Senior Thesis-Introduction" http://www.sar.usf.edu/~sudberry/thesis/intro.html December 11, 2000
	21	"Rule RB-1.1 and Tables 1 and 2-Revison of the extended Hantzsc-Widman system of nomenclature for heteromonocycles", http://www.chem.qmw.ac.uk/iupac/hetero/HW1nT.html , December 26, 2000
CK	22	"Luteinizing Hormone-Releasing Hormone (LHRH) Neuronal System: From Basic to Clinical", Serge Rivest and Leonello Cusan, Laboratory of Molecular Endocrinology, pp 1-27, http://www.acnp.org/G4/GN401000058/CH058/html , December 26, 2000

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17324CIP1	RECEIVED SEP 11 2002 PATENT & TRADEMARK OFFICE	SERIAL NO.: 09/810,601
APPLICANT: DONOVAN	TITLE: COMPOSITIONS AND METHODS FOR TREATING GONADOTROPHIN RELATED ILLNESSES	
FILING DATE: March 15, 2001	GROUP: 1653	

UNITED STATES PATENTS

*EXAMINE R INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CMK	AA	5,707,964	01/13/98	Nett, et al.			
	AB	5,939,070	08/17/99	Johnson, et al.			
CMK	AC	5,989,545	11/23/99	Foster, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
CMK	BA	WO 90/09799	07.09.90	PCT			
	BB						

PUBLICATIONS

*EXAMINE R INITIAL		AUTHOR, TITLE, JOURNAL AND PUBLICATION DATE
	CA	
	CB	
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	
	CI	
	CK	
	CL	

RECEIVED
SEP 16 2002
TECH CENTER 1600/2900

Duplicate

EXAMINER

Ch

DATE CONSIDERED

4/17/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.